Chiron Real Estate
Chiron Real Estate's revenue rose 6.8% to $148 million in fiscal 2025. Its net margin was −4.6%, down from 4.8% a year earlier. It paid out $12 million in dividends and buybacks. The diluted share count rose 1.5%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2018 to 2024, earnings per share fell 43.0% a year and net income 12.2% a year, as new shares raised the share count by 200% and diluted each share's earnings. Chiron Real Estate then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 7 | 4 | 1 | 7 | 9 |
| Debt incl. finance leases | — | — | — | 14 | 1 |
| Net debt (negative means net cash) | — | — | — | 8 | −8 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Cash flow
Projections
Project Chiron Real Estate's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 12 insiders bought $3.5 million of Chiron Real Estate shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Matthew Fitzsimmons WhitlockChief Investment Officer | Bought | 500 | $36.38 | $18,190 | Form 4 |
| Aug 14, 2026 | Matthew Fitzsimmons WhitlockChief Investment Officer | Bought | 500 | $37.21 | $18,605 | Form 4 |
| Aug 12, 2026 | Aaron Robert RosethCOO, Director | Bought | 13,500 | $36.73 | $495,855 | Form 4 |
| Aug 11, 2026 | Charles FitzgeraldDirector | Bought | 14,000 | $35.78 | $500,920 | Form 4 |
| Aug 11, 2026 | Mark Okey Decker JrCEO and President, Director | Bought | 6,875 | $35.92 | $246,950 | Form 4 |
| Aug 11, 2026 | Mark Okey Decker JrCEO and President, Director | Bought | 550 | $36.00 | $19,800 | Form 4 |
| Aug 10, 2026 | Charles FitzgeraldDirector | Bought | 27,600 | $35.94 | $991,944 | Form 4 |
| Aug 10, 2026 | Mark Okey Decker JrCEO and President, Director | Bought | 8,000 | $35.88 | $287,040 | Form 4 |
| May 14, 2026 | Matthew CypherDirector | Bought | 1,420 | $35.12 | $49,870 | Form 4 |
| May 12, 2026 | Mark Okey Decker JrCEO and President, Director | Bought | 5,000 | $33.94 | $169,700 | Form 4 |
| May 12, 2026 | Lori WittmanDirector | Bought | 2,940 | $33.85 | $99,519 | Form 4 |
| May 12, 2026 | Ronald MarstonDirector | Bought | 1,500 | $34.07 | $51,112 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | — | — | — |
| Accruals ratio | −3.5% | −5.0% | −6.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | — | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Chiron Real Estate side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Chiron Real Estate | FY25 | 6.8% | — | — | — | — | — | |
| Strawberry Fields REIT | FY25 | 32.4% | 54.4% | — | 8.8% | 5.8x | — | Compare |
| Community Healthcare Trust | FY25 | 4.7% | — | 29.6% | 3.2% | 7.0x | — | Compare |
| Universal Health Realty Income Trust | FY25 | 0.2% | 35.0% | — | 5.2% | 5.8x | — | Compare |
| LTC Properties | FY25 | 25.3% | 77.9% | 49.0% | 11.0% | 3.4x | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 8 | 30 | 53 | 71 | 94 | 116 | 137 | 141 | 139 | 148 |
| Revenue growth | 298.2% | 269.6% | 75.3% | 33.0% | 32.5% | 23.7% | 18.4% | 2.7% | −1.6% | 6.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | −6 | −0 | 15 | 10 | −2 | 18 | 20 | 22 | 7 | −7 |
| Diluted EPS (US$) | −3.40 | −0.45 | 1.75 | 0.50 | −0.85 | 0.95 | 1.00 | 1.13 | 0.06 | −0.91 |
| Diluted shares (millions) | 2 | 4 | 4 | 7 | 9 | 12 | 13 | 13 | 13 | 13 |
| Cash flow | ||||||||||
| Cash from operations | −2 | 13 | 25 | 36 | 34 | 69 | 76 | 68 | 70 | 74 |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | 0 | 1 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Acquisitions | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 3 | 3 | 5 | 6 | 5 | 4 | 5 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 5 | 4 | 3 | 6 | 7 | 4 | 1 | 7 | 9 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 14 | 1 |
| Total assets | 227 | 472 | 636 | 885 | 1,101 | 1,264 | 1,393 | 1,268 | 1,256 | 1,242 |
| Total liabilities | 72 | 213 | 336 | 425 | 643 | 626 | 744 | 662 | 701 | 712 |
| Shareholders' equity | 155 | 246 | 269 | 430 | 445 | 623 | 633 | 584 | 534 | 510 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | −77.4% | −0.3% | 27.4% | 13.6% | −2.7% | 15.8% | 14.6% | 15.4% | 4.8% | −4.6% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −8.2% | −0.0% | 5.7% | 2.7% | −0.6% | 3.4% | 3.2% | 3.6% | 1.2% | −1.3% |
| Return on assets | −4.3% | −0.0% | 2.6% | 1.3% | −0.2% | 1.6% | 1.5% | 1.6% | 0.5% | −0.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |